Table 2.
Clinical findings, side effects and treatment outcomes
| Clinical findings | All patients (36) | Warfarin (13) |
Rivaroxaban (23) | P value |
|---|---|---|---|---|
| Duration of hospitalization (days) | 16.77 ± 10.69 | 11.7 ± 7.61 | 0.133 | |
| Loss of consciousness | 7 (19.44%) | 0.382 | ||
| Yes | 1 (7.7%) | 6 (26.1%) | ||
| No | 12 (92.3%) | 17 (73.9%) | ||
| Outcomes of treatment | ||||
| Minor bleeding | 5 (15.63%) | 2/10 (20%) | 3/22 (13.63) | 0.708 |
| Major bleeding | 0 | 0 | 0 | |
| mRS | 32a | 10 | 22 | > 0.999 |
| mRS (0 or 1) | 28 (87.5%) | 9 (90%) | 19 (86.36%) | |
| mRS 2 | 4 (12.5%) | 1 (10%) | 3 (13.63%) | |
| MRV (Recanalization) | 19a | 5 | 14 | > 0.999 |
| Recanalized | 17 (93.75%) | 5 (100%) | 12 (85.71%) | |
| Complete | 14 (84.37%) | 4 (80%) | 10 (83.33%) | |
| Partial | 3 (9.38%) | 1 (20%) | 2 (16.67%) | |
| Not recanalized | 2 (6.25%) | 0 | 2 (14.29%) | |
mRS modified ranking scale, MRV magnetic resonance venography. Quantitative statistics were shown using Mean and Standard Deviations, Mean ± (SD)
a The number of the statistical population in the follow-up (mRS and MRV) was lower than the initial population due to not answering the phone call or unwillingness to participate in follow-up